Mural Oncology plc
CIK:
0001971543
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Emerging growth company
State of Incorporation
Ireland
Business Address
10 EARLSFORT TERRACE, DUBLIN 2, L2, D02 T380
Mailing Address
10 EARLSFORT TERRACE, DUBLIN 2, L2, D02 T380
Phone
353 1 905 8020
Fiscal Year End
1231
EIN
000000000
Financial Overview
FY2024
-$128.51M
Net Income
$301.75M
Total Assets
$37.93M
Total Liabilities
$-7.58
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13G/A Passive ownership amendment | December 16, 2025 | View on SEC |
| 4 Insider stock transaction report | December 5, 2025 | View on SEC |
| 4 Insider stock transaction report | December 5, 2025 | View on SEC |
| 4 Insider stock transaction report | December 5, 2025 | View on SEC |
| 4 Insider stock transaction report | December 5, 2025 | View on SEC |
| 4 Insider stock transaction report | December 5, 2025 | View on SEC |
| 4 Insider stock transaction report | December 5, 2025 | View on SEC |
| 4 Insider stock transaction report | December 5, 2025 | View on SEC |
| 4 Insider stock transaction report | December 5, 2025 | View on SEC |
| 8-K Current report of material events | December 5, 2025 | View on SEC |
Material Events
8-K
Acquisition
December 5, 2025
High Impact
- Mural Oncology plc has been acquired by XOMA Royalty Corporation, through its subsidiary XRA 5 Corp.
- Mural Oncology is no longer an independent public company and its stock will be delisted from The Nasdaq Global Market.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.